Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action

Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established....

Descripción completa

Detalles Bibliográficos
Otros Autores:	Allison, Simon J (Editor)
Formato:	Libro electrónico
Idioma:	Inglés
Publicado:	MDPI - Multidisciplinary Digital Publishing Institute 2022
Materias:	Technology: general issues History of engineering & technology microtubule acetylation triple-negative breast cancer anti-cancer agent apoptosis K562 8-hydroxydaidzein autophagy BCR-ABL MAPK NF-κB c-myc RNA interference siRNA oncogene gene silencing expression nanosystems Cytochrome P450 CYP1A1 CYP1B1 CYP2W1 breast cancer prodrug bioprecursor duocarmycin phortress AQ4N 5-FU resistance colorectal cancer drug repurposing Genomics of Drug Sensitivity in Cancer Connectivity Map anticancer drug B-lactam steroid alkylators synthetic lethality poly (ADP-ribose) polymerase inhibitors ovarian cancer hybrid steroidal alkylating agents migration invasion glioblastoma CCN1 mesenchymal-amoeboid transition biomarker HepG2 Huh7 isatin sulfonamides angiogenesis cancer hallmarks molecular docking EGFR tyrosine kinase inhibitor photon upconversion triplet-triplet annihilation in vivo imaging PLGA nanoparticles affibody molecule human epidermal growth factor receptor 3 (HER3) BxPC-3 emtansine DM1 albumin binding domain affibody drug conjugate (AffiDC)
Ver en Biblioteca Universitat Ramon Llull:	https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009689919806719